What is Amoéba?
Amoéba is at the forefront of environmental health, specializing in the development of innovative biological treatments derived from a unique microorganism, Willaertia magna. This naturally occurring agent possesses the capability to combat harmful bacteria, offering a sustainable and chemical-free alternative to traditional antimicrobial methods. The company's product portfolio targets critical sectors including industrial water systems, wound care, and plant protection, providing effective solutions for controlling dangerous microbes such as legionella in environments like industrial cooling towers. Amoéba's approach represents a significant shift towards eco-friendly and safe microbial management.
How much funding has Amoéba raised?
Amoéba has raised a total of $4.6M across 1 funding round:
Stock/Share Issuance
$4.6M
Stock/Share Issuance (2026): $4.6M with participation from Vatel Capital
Key Investors in Amoéba
Vatel Capital
Vatel Capital is a financial services firm focused on wealth management and tax optimization in France, providing personalized strategies for investment growth and tax reduction.
What's next for Amoéba?
With the recent infusion of major strategic capital, Amoéba is poised to accelerate its research and development initiatives and expand its market reach. The company's focus on biological solutions for microbial control aligns with a growing global demand for sustainable and non-chemical alternatives. This enterprise-level backing will likely enable Amoéba to scale its production capabilities, enhance its product offerings, and penetrate new markets, further solidifying its position as a leader in the environmental health sector. The strategic investment suggests confidence from backers in Amoéba's technology and its potential for significant impact across various industries.
See full Amoéba company page
